MK-2214 is an investigational biological therapy developed by Merck Sharp & Dohme LLC (MSD) in development for the treatment of early Alzheimer's disease. The drug is currently being evaluated in a Phase 2 clinical trial (NCT07033494) targeting patients with early-stage disease, including those with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease dementia.
| Attribute | Value |
|---|---|
| NCT Number | NCT07033494 |
| Sponsor | Merck Sharp & Dohme LLC |
| Phase | Phase 2 |
| Status | Recruiting |
| Start Date | July 16, 2025 |
| Estimated Completion | April 30, 2029 |
| Duration | ~3.5 years |
| Intervention | MK-2214 (Biological) via IV infusion |
| Dosage | Every 4 weeks |
Eligibility Criteria:
The study is a randomized, placebo-controlled trial evaluating the safety and efficacy of MK-2214 administered via intravenous infusion every 4 weeks.
Cognitive Assessments:
Additional Tau PET composite measures
The trial is being conducted at multiple sites across:
While the specific mechanism of MK-2214 has not been disclosed, the trial's focus on tau PET imaging as a primary outcome suggests the drug may target tau pathology. The tau PET endpoint measures the accumulation or spread of tau neurofibrillary tangles, which correlate with disease progression and cognitive decline in Alzheimer's disease.
MK-2214 joins a growing field of tau-targeted therapies in development:
| Agent | Company | Target | Stage |
|---|---|---|---|
| MK-2214 | Merck | Tau (specific undisclosed) | Phase 2 |
| Semorinemab | Roche/Genentech | Tau antibody | Phase 2 |
| E2814 | Eisai | Tau aggregation inhibitor | Phase 2 |
| BIIB080 (MAPTRx) | Biogen/Ionis | Tau ASO | Phase 2 |
| JNJ-63733657 | J&J | Tau antibody | Phase 1 |
Tau pathology correlates more closely with cognitive decline than amyloid in Alzheimer's disease:
By targeting tau, MK-2214 aims to slow or halt disease progression in patients with early AD who already have established tau pathology.
This trial incorporates several modern design elements:
Primary endpoints (multiple):
Key secondary endpoints:
| Drug | Route | Frequency | Key Advantage |
|---|---|---|---|
| MK-2214 | IV | Every 4 weeks | Merck's AD expertise |
| Lecanemab | IV | Every 2 weeks | Approved, amyloid removal |
| Donanemab | IV | Every 4 weeks | Approved, plaque removal |
| Semorinemab | IV | Monthly | Broad tau targeting |
If approved, MK-2214 would compete in the anti-tau therapeutic space:
Tau-targeted therapies may have specific safety considerations:
| Risk | Mitigation |
|---|---|
| ARIA (amyloid-related imaging abnormalities) | MRI monitoring, exclusion criteria |
| Infusion reactions | Pre-medication, slow infusion |
| Immunogenicity | Antibody engineering |
The trial includes:
Tau PET imaging has emerged as a critical biomarker in Alzheimer's disease clinical trials, allowing direct visualization of tau pathology in the brain. By targeting tau pathology, MK-2214 represents a disease-modifying approach that addresses one of the key hallmarks of Alzheimer's disease alongside amyloid-beta.
This trial targets early AD because: